A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes.
Journal Information
Full Title: CPT Pharmacometrics Syst Pharmacol
Abbreviation: CPT Pharmacometrics Syst Pharmacol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"CONFLICT OF INTEREST STATEMENT V.S., T.Y., and L.S. are employees of M&S Decisions LLC, a modeling consultancy contracted by AstraZeneca. T.Y. owns AstraZeneca stock or stock options. R.C.P., D.B., J.P., and W.T. are employees of AstraZeneca and own AstraZeneca stock or stock options."
Funding Disclosure
Evidence found in paper:
"FUNDING INFORMATION This study was funded by AstraZeneca."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025